Therapeutic mammoplasty: An advanced oncoplastic breast surgery technique

Share :
Published: 16 Jul 2026
Views: 669
Rating:
Save
Dr Sanjit Agrawal - Tata Medical Center, Kolkata, India

Dr Sanjit Kumar Agrawal speaks to ecancer about therapeutic mammoplasty, an advanced oncoplastic breast surgery technique that integrates effective tumour removal with immediate breast reshaping.

This approach allows surgeons to achieve clear oncological margins while delivering significantly improved cosmetic outcomes compared with standard breast conserving surgery.

Particularly suited for patients with larger or denser breasts and higher tumour to breast volume ratios, therapeutic mammoplasty expands eligibility for breast conservation while also enhancing postoperative symmetry and overall quality of life.

In this presentation, Dr Agrawal outlines key surgical techniques, patient selection considerations, and strategies for managing complications.

He also shares real world outcome data from his institutional audit, demonstrating the safety, effectiveness, and aesthetic benefits of this evolving approach in modern breast cancer care.

Related Videos

Giredestrant plus palbociclib shows limited benefit in ER-positive, HER2-negative metastatic breast cancer

Dr Mabel Mardones - Rocky Mountain Cancer Centers, Denver, USA
Giredestrant plus palbociclib shows limited benefit in ER-positive, HER2-negative metastatic breast cancer ( Dr Mabel Mardones - Rocky Mountain Cancer Centers, Denver, USA )
10 Jun 2026

Sacituzumab govitecan improves PFS across Trop-2, BRCA, and HER2 metastatic triple-negative breast cancer

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA
Sacituzumab govitecan improves PFS across Trop-2, BRCA, and HER2 metastatic triple-negative breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )
9 Jun 2026

Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA
Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )
9 Jun 2026

Gene expression test guided therapy in ER+/HER2- early breast cancer allows safe chemotherapy omission

Dr Robert Stein - University College London, London, UK
Gene expression test guided therapy in ER+/HER2- early breast cancer allows safe chemotherapy omission ( Dr Robert Stein - University College London, London, UK )
1 Jun 2026

Xaluritamig plus abiraterone shows promising anti-tumour activity with manageable safety in chemotherapy-naïve mCRPC

Dr David Pook - Monash Health, Melbourne, Australia
Xaluritamig plus abiraterone shows promising anti-tumour activity with manageable safety in chemotherapy-naïve mCRPC ( Dr David Pook - Monash Health, Melbourne, Australia )
1 Jun 2026

Screen-detectable cancers account for majority of early-onset cancer cases under age 50

Prof Aldenise Ewing - The Ohio State University, Colombus, USA
Screen-detectable cancers account for majority of early-onset cancer cases under age 50 ( Prof Aldenise Ewing - The Ohio State University, Colombus, USA )
1 May 2026

ctDNA positivity predicts poor response and recurrence risk in triple-negative breast cancer

Dr Priya Rastogi - NSABP Foundation & University of Pittsburgh School of Medicine, Pittsburgh, USA
ctDNA positivity predicts poor response and recurrence risk in triple-negative breast cancer ( Dr Priya Rastogi - NSABP Foundation & University of Pittsburgh School of Medicine, Pittsburgh, USA )
28 Apr 2026

Daraxonrasib plus chemotherapy shows promising first-line activity in RAS-mutant metastatic pancreatic cancer

Dr Brian Wolpin - Dana-Farber Cancer Institute, Boston, USA
Daraxonrasib plus chemotherapy shows promising first-line activity in RAS-mutant metastatic pancreatic cancer ( Dr Brian Wolpin - Dana-Farber Cancer Institute, Boston, USA )
27 Apr 2026

Abemaciclib combined with endocrine therapy improves OS in high-risk HR+, HER2− early breast cancer

Prof Stephen Johnston - The Royal Marsden, London, UK
Abemaciclib combined with endocrine therapy improves OS in high-risk HR+, HER2− early breast cancer ( Prof Stephen Johnston - The Royal Marsden, London, UK )
19 Oct 2025